Ascent Wealth Partners LLC Has $470,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Ascent Wealth Partners LLC decreased its stake in Johnson & Johnson (NYSE:JNJ) by 5.8% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,218 shares of the company’s stock after selling 197 shares during the quarter. Ascent Wealth Partners LLC’s holdings in Johnson & Johnson were worth $470,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of JNJ. GUNN & Co INVESTMENT MANAGEMENT INC. boosted its position in shares of Johnson & Johnson by 1,194.9% in the fourth quarter. GUNN & Co INVESTMENT MANAGEMENT INC. now owns 237,273 shares of the company’s stock worth $37,190,000 after buying an additional 218,949 shares during the period. Gilbert & Cook Inc. increased its holdings in shares of Johnson & Johnson by 3.3% in the 4th quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company’s stock valued at $1,428,000 after purchasing an additional 288 shares during the period. Altrius Capital Management Inc lifted its position in shares of Johnson & Johnson by 0.7% in the fourth quarter. Altrius Capital Management Inc now owns 22,597 shares of the company’s stock worth $3,542,000 after purchasing an additional 147 shares in the last quarter. Steele Capital Management Inc. acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $305,000. Finally, LWM Advisory Services LLC grew its position in Johnson & Johnson by 3.5% during the fourth quarter. LWM Advisory Services LLC now owns 2,200 shares of the company’s stock valued at $345,000 after purchasing an additional 75 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $165.86 on Monday. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $165.98. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The company has a market cap of $399.26 billion, a price-to-earnings ratio of 10.34, a PEG ratio of 2.73 and a beta of 0.52. The firm’s 50-day moving average is $155.68 and its 200-day moving average is $153.47.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. During the same quarter in the prior year, the business posted $2.80 earnings per share. The company’s quarterly revenue was up 4.3% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 2.99%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s payout ratio is presently 30.92%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of research reports. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research note on Thursday, July 18th. Royal Bank of Canada restated an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research note on Tuesday, July 30th. TD Cowen cut their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Finally, Sanford C. Bernstein raised their price objective on shares of Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $173.21.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.